Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.

"This study was supported by Stichting Macula Fonds; Retina Nederland Onderzoek Fonds; Stichting Blinden‐Penning; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Landelijke Stichting voor Blinden en Slechtzienden, which contributed through UitZicht (Delft, the Netherlands); Rotterdamse Stichting Blindenbelangen (Rotterdam, the Netherlands); Stichting Leids Oogheelkundig Ondersteuningsfonds (Leiden, the Netherlands); Haagse Stichting Blindenhulp (The Hague, the Netherlands); Stichting Ooglijders (Rotterdam, the Netherlands); Stichting Blindenhulp; Oxford NIHR Biomedical Research Centre (Oxford, United Kingdom); the Gisela Thier Fellowship of Leiden University, Leiden, the Netherlands (C.J.F.B.); and the Netherlands Organization for Scientific Research (VENI grant to C.J.F.B.). These funding organizations provided unrestricted grants and had no role in the design or conduct of this research. This investigator‐initiated study received funding from Novartis Pharma B.V. (Arnhem, the Netherlands) solely for the purchase of verteporfin (Visudyne) to enable photodynamic therapy treatment at the Oxford site, because photodynamic therapy currently is not reimbursed routinely by the United Kingdom National Health Service for treating central serous chorioretinopathy. Novartis Pharma B.V. had no role in funding, designing, conducting or evaluating the study, nor in the writing of this manuscript."